Skip to main content
Premium Trial:

Request an Annual Quote

Simulations Plus, FDA to Collaborate on Drug Development Study

Premium

Simulations Plus said this week that it has signed a five-year research collaboration agreement with the US Food and Drug Administration to work on determining the value of mechanistic absorption modeling (MAM) in developing predictive and robust in vitro/in vivo correlations.

Specifically, the collaborators will explore how MAM can be used to make more accurate predictions of complex drug absorption characteristics. The ultimate goal of the project, the company said in a statement, is to "facilitate drug and generic product development by decreasing the regulatory burden through adequate modeling approaches."

As part of the agreement, Simulations Plus will provide training and licenses for its GastroPlus simulation software to the FDA's Office of Testing and Research. The solution will be used to "model in vivo data [that is] representative of challenging absorption characteristics, the company said.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.